Health Care Equipment & Services

Insightful look at Sophia Genetics insider sales, liquidity strategy, market impact, and future growth prospects in precision‑medicine.

Insider buying fuels optimism for Daxor Corp as CEO’s fresh FDA‑cleared blood‑volume‑analysis service meets rising chronic‑disease market demand and reimbursement opportunities.

Hologic’s merger with Hopper Parent Inc. sees insiders liquidate shares, boosting cash and reshaping valuation—key insights for investors navigating the transition.

Investor insights on Hologic’s insider sale post‑merger: strategic exit, CVR impact, dilution risks, and growth outlook.

Insider sales reveal the impact of a healthcare‑tech merger on stock value, reimbursement trends, and AI‑driven growth.

Hologic insiders sold 2.4 M shares on the day a Blackstone/TPG deal was announced, yet kept performance‑stock units, showing confidence in the company’s future value after going private.

Insightful insider trading at Baxter International reveals how executives balance short‑term liquidity with long‑term value, highlighting potential growth in high‑margin therapeutics and digital health integration for investors.

ResMed CEO’s latest 10b‑5‑1 trades show disciplined buying at lower prices and selling at a premium—signaling confidence while hedging risk, with implications for investors and market dynamics.

HealthEquity’s CTO exit sparks insider sales and raises questions about future tech plans – discover how leadership changes could affect the stock’s trajectory.

Alignment Healthcare’s CFO sell‑to‑cover move boosts confidence as insiders buy, while the company’s oncology, diabetes, and rare‑disease programs show strong safety, efficacy and timely regulatory milestones.